THERAPY DOSSIER · th-d930047f0079

miR-146a-5p overexpression

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Crush
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28510617 ↗2017Reported benefit

miR-146a-5p acts as a negative regulator of TGF-beta signaling in skeletal muscle after acute contusion.

MouseCrushLimb / muscle crushMale

Model: Acute skeletal muscle contusion producing muscle fibrosis

miR-146a-5p was reduced in contused muscle and its overexpression suppressed fibrosis marker expression in vitro and in vivo, an effect blocked by Smad4 overexpression, indicating an antifibrotic role within TGF-beta signalling.

Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…